Egisto Boschetti, Ph.D., M.B.A.: Chief Scientific Officer
Internationally recognized as an expert in protein separation by liquid chromatography, Dr. Boschetti served Ciphergen Biosystems Inc as Vice President R&D between 2002 and 2006. Previously he had a position as Research Director at BioSepra and its predecessors as far back as the inception of the business in the beginning of ‘80s.
With a degree in biochemistry from the University of Bologna (Italy) and an MBA, (Paris), Dr. Boschetti is one of the co-founders of Biosphere Medical, where he served as President at the early stage of the Company development. His extensive experience in the domain of proteins is witnessed by over 220 scientific publications in international journals and books, and the application of more than 60 patents. In the last few years, he has developed biochips for protein analysis by mass spectrometry. Major recent accomplishments in the bio-purification domain are the design of a variety of composite solid phase sorbents, coupling chemistry, ligand design and immobilization. In proteomics field a major achievement is the reduction of dynamic concentration range and concomitant discovery of many low-abundance species.
Professor Richard G. Compton
Professor Compton is a Professor of Chemistry at Oxford University and Tutor in Chemistry at St John’s College. He is Editor-in-Chief of the journal Electrochemistry Communications and has published over 900 papers and reviews in refereed journals. He has broad interests in electrochemistry and electroanalysis. His outstanding contribution to the field of electrochemistry has been widely recognized within the scientific community through numerous awards, most recently the Tilden Lecturer in Physical Chemistry of the Royal Society of Chemistry (2006) and the Breyer Medal of the Royal Australian Chemistry Institute (2007). Richard was also the recipient of the Electrochemical Society’s Alessandro Volta Medal. He is the first, and only recipient of both RSC medals in electrochemistry and electroanalysis. Richard is a co-founder of the drug testing spin-out company OxTox and is a co-inventor of the proprietary pH sensing technology currently being developed by Senova.
Professor Joseph Wang
Professor Wang is a world-renowned expert in sensor technology and electrochemistry. He was an original innovator of non-invasive glucose sensors and continues to make significant academic and industrial contributions in sensors for industry, healthcare, environment, and security applications. He is founder and Editor-in-Chief of the journal Electrochemistry and has consistently been one of the most widely cited engineers and chemists in the world. He currently heads up the NanoEngineering Department at the University of California at San Diego, the leading institution in the U.S. in this field.
Professor Attilio Citterio
Professor Citterio is a Professor of Chemistry at Politecnico di Milano. He has broad interests in synthetic sustainable chemistry, mechanism and kinetics of homolytic reactions, analytical chemistry and interfacial engineering. He is a recognized expert in the field of organic synthesis and surface chemical derivatization of natural/artificial polymers and carbon materials, e.g. carbon nanotubes. He has a great deal of experience in the preparation of multifunctional coating materials and their applications. Prof. Citterio has published over 145 papers and reviews and is an inventor of 52 patents.
Dr. Gregory G. Wildgoose
Dr. Wildgoose completed his MChem and DPhil in 2003 and 2006 respectively at Oxford University. In 2006 he was elected as a Junior Research Fellow at St John’s College, Oxford. He has published over 75 papers and is a referee for several international journals. He has broad interests in electrochemistry and electroanalysis in conjunction with other surface analysis techniques such as XPS, AFM etc. In particular he has expertise in the field of chemically-modified carbon and carbon nanotube chemistry. Greg is also a co-inventor of the proprietary pH sensing technology currently being developed by Senova.
Herbert Heyneker, Ph.D.
After receiving his PhD degree in Molecular Genetics in 1975 from the University of Leiden, the Netherlands, Dr. Heyneker started post-doctoral work in the laboratory of Prof. Herbert Boyer at UCSF. The following year, when Boyer and Swanson founded Genentech, he was hired as the first scientist. At Genentech, his lab was responsible for the co-expression of the light and heavy chain genes coding for an IgG antibody in E. coli (protected by the Cabilly I and II patents). In 1984 he joined Genencor, a spin-off from Genentech, as VP Research. In the 90s, he co-founded three biotechnology companies including Eos, a functional genomics company, where he was the Chief Technology Officer. At Eos, he designed a highly parallel DNA synthesis instrument (US patent 6,264,891) that was used by a wholly-owned subsidiary to sell oligos over the web and later acquired by Invitrogen. After Eos was acquired by Protein Design Labs, he joined Abingworth as an advisor. In 2008, he also became an advisor for Thuja Capital. He has served on the Board of Directors for GenPharm, Guava Technologies, IntroGene (now Crucell), Pharming, Pepscan and Prosensa. Currently he is a board member of Profibrix and Boreal Genomics. He consults for a range of biotechnology companies in the US and Europe and is an author on more than 50 papers and an inventor on more than 30 US patents.
Robert Bratzler, Ph.D.
Dr. Bratzler has 25 years of experience in the biotechnology industry. He most recently served as President and CEO of Coley Pharmaceutical Group , which he led from inception through to a successful IPO and its eventual acquisition by Pfizer in January, 2008. Previously, he co-founded Sepracor Inc., a research-based pharmaceutical company, where he helped build and finance several Sepracor group companies, including ChiRex Inc., a pharmaceutical outsourcing company, which had a successful IPO in 1996. There, Robert served as President and Chief Executive Officer. A former faculty member in the department of chemical engineering at Princeton University, he received his B.S. degree from the University of Michigan and his Ph.D. in chemical engineering from the Massachusetts Institute of Technology. He currently serves on the Board of Directors of several private biotechnology companies.
Andreas Kyriacou, Ph.D.
Upon obtaining his PhD degree in Biochemical Engineering, Dr. Kyriacou worked in the food, pharmaceutical device and biopharmaceutical industries, his career spanning the disciplines of process and product development, technology transfer, project management, manufacturing, quality and executive management. He spent the last 16 years of his corporate career at Amgen, Inc. He currently is an independent consultant to the pharmaceutical/biotechnology industries as well as an adjunct professor in the biotechnology departments of California State University Channel Islands and Moorpark College.
As a member of Genentech’s Fermentation Department, Mr. Iverson was involved in process development and manufacturing implementation of new bioprocessing technologies, and commissioning of Genentech’s first commercial scale mammalian cell culture facility. In 1988, Kent moved to Immunex and was involved in two additional GMP facilities projects, the development of Immunex’s first two commercial biopharmaceuticals. He joined Coulter Pharmaceuticals in 1997, where he lead the Manufacturing and Process Development functions of the company, directing the CMC development of Bexxar and a pipeline of targeted delivery and antibody-based therapies. He has been an independent biologics CMC consultant since 2001, specializing in contract manufacturer selection and management, recombinant protein process and CMC development, process economics modeling, due diligence, facility design and process troubleshooting. Mr. Iverson holds a Bachelor’s of Science degree from the University of California at Davis.
Kevin Kaster, J.D.
Mr. Kaster has developed patent and licensing strategies for important technologies and drug products. He was formerly the VP of Corporate Development at Threshold Pharmaceuticals, a publicly traded biotechnology company. Prior to Threshold, he was the VP of Intellectual property at Kosan Biosciences, acquired by Bristol-Myers Squibb in 2008. Prior to Kosan, he was the VP of Intellectual Property at Geron Corporation, where he developed the company’s patent portfolio protecting telomerase and human embryonic stem cell technologies. Prior to Geron, he was Director of Intellectual Property at Affymax, where he managed the intellectual property that led to Affymetrix (DNA Chip technology) and Maxygen (DNA Shuffling technology). He also managed the PCR patent portfolio as a Senior Patent Attorney at Cetus Corporation. Mr. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician. He received his law degree from Indiana University School of Law and his Bachelor of Science degree magna cum laude from Vanderbilt University in Chemistry.